Transferring patients with refractory hypoxemia to a regional extracorporeal membrane oxygenation center: key considerations for clinicians.

AACN Adv Crit Care

Christine S. Schulman is Critical Care Clinical Nurse Specialist, Legacy Health, 1225 NE 2nd Ave, Portland, OR 97232 Christopher Bibro is Neurotrauma ICU Staff Nurse, ECMO Specialist, Legacy Health, Portland, Oregon. Diane Braxmeyer Downey is Neurotrauma ICU Supervisor, ECMO Specialist, Legacy Health, Portland, Oregon. Christine Lasich is Neurotrauma ICU Staff Nurse, ECMO Specialist, and Adult ECMO Education Coordinator, Legacy Health, Portland, Oregon.

Published: September 2016

Because of technological advancements and encouraging experiences during the 2009 influenza A (H1N1) epidemic, many critical care clinicians consider extracorporeal membrane oxygenation (ECMO) a reasonable strategy for managing patients with refractory hypoxemia when standardized therapies have failed. Although the literature remains unclear as to whether it should be considered a routine or a rescue strategy in the management of patients with severe acute respiratory distress syndrome, experts agree that ECMO therapy is most likely to result in positive outcomes and fewer complications when provided at regional ECMO centers. Some institutions have developed the expertise and resources required to provide this sophisticated therapy, but significantly more facilities may choose to send their patients to a tertiary ECMO center when they do not respond to usual care. This article provides information essential for health care teams who refer their patients to such centers. The clinical indications for, and the use of, ECMO therapy in the management of refractory hypoxemia is briefly reviewed, followed by a description of how ECMO works to provide gas exchange and tissue perfusion. The primary considerations for circuit management, hemodynamic support, and pulmonary care are described, and significant complications of the therapy are identified. The remainder of the article focuses on the patient care and preparatory activities that occur before and during ECMO initiation, so that health care teams, patients, and their families can be confident of an efficient, safe, and highly skilled transfer of care between institutions.

Download full-text PDF

Source
http://dx.doi.org/10.1097/NCI.0000000000000054DOI Listing

Publication Analysis

Top Keywords

refractory hypoxemia
12
patients refractory
8
extracorporeal membrane
8
membrane oxygenation
8
ecmo therapy
8
health care
8
care teams
8
care
7
ecmo
7
patients
5

Similar Publications

Recirculation in Veno-Venous Extracorporeal Membrane Oxygenation.

Medicina (Kaunas)

November 2024

Department of Anesthesiology and Intensive Care, University of Padua, 35129 Padova, Italy.

This review focuses on recirculation in the context of Veno-Venous Extracorporeal Life Support in adults. The methods employed to calculate and quantify the extent of recirculation, as well as factors affecting recirculation and interventions that could reduce recirculation, are detailed. As recirculation may significantly reduce extracorporeal oxygen delivery, leading to refractory hypoxemia, detecting and quantifying the recirculation fraction is fundamental in order to optimize VV-ECMO lung support.

View Article and Find Full Text PDF

Purpose: Hypoxemia is a risk factor for mortality and long-term neuropsychological impairment during severe acute respiratory distress syndrome (ARDS). Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is a potential treatment for such cases but may not suffice. We aimed to evaluate the effects of pharmacological interventions for cardiac output (CO) control using ivabradine or beta-blockers for refractory hypoxemia during VV-ECMO.

View Article and Find Full Text PDF

Antiangiogenic drugs may cause vascular normalization and correct hypoxia in tumors, shifting cells to mitochondrial respiration as the primary source of energy. In turn, the addition of an inhibitor of mitochondrial respiration to antiangiogenic therapy holds potential to induce synthetic lethality. This study evaluated the mitochondrial inhibitor ME-344 in combination with bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).

View Article and Find Full Text PDF

Lung Transplant Success in COVID-19 Patients Requiring V-V ECMO: One-Year Follow-Up.

Ann Transplant

December 2024

Division of Pulmonary Medicine, Critical Care, Sleep Medicine, and Physiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.

BACKGROUND Acute respiratory distress syndrome (ARDS) due to coronavirus 2019 (COVID-19) can result in severe disease requiring mechanical ventilatory support. A subset of these patients, however, demonstrate refractory hypoxemia/hypercarbia requiring veno-venous extracorporeal membrane oxygenation (V-V ECMO) as adjunctive therapy. The primary goal of V-V ECMO is a "bridge" to recovery of native lung function; however, patients may progress to irreversible pulmonary damage requiring lung transplantation.

View Article and Find Full Text PDF

When encountering severe hypoxemia that does not respond to oxygen supplementation, it is essential to consider underlying right-to-left shunting. Among various diagnostic approaches, the microbubble test via transthoracic echocardiography (TTE) is a simple, noninvasive method for detecting pulmonary arteriovenous shunts, particularly in hepatopulmonary syndrome (HPS). Although microbubbles are usually administered peripherally, using a Swan-Ganz (SG) catheter to inject microbubbles directly into the pulmonary artery may provide even more definitive diagnostic information.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!